ATTOVIA THERAPEUTICS ANNOUNCES $90 MILLION SERIES C FINANCING TO ADVANCE ATTOBODY-BASED PROGRAMS THROUGH CLINICAL PROOF OF CONCEPT
Further company coverage: [ ]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.